Organon & Co is a leading pharmaceutical company based in the United States, with a medium ESG risk rating score of 23.3. Specializing in women's health, biosimilars, and established brands, Organon & Co develops and delivers cutting-edge health solutions globally. The company generates the majority of its revenue from its Established Brands product portfolio and operates in Europe, Canada, the United States, as well as Asia Pacific and Japan.